# Theator

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/theator

- Industry: Software
- Headquarters: Palo Alto, US
- Website: www.theator.io
- Total disclosed funding: $42M
- Latest round: Series A (Jul 22, 2022)
- Investors on record: 8

## About

Theator Inc. is a healthcare technology company specializing in Surgical Intelligence solutions that convert surgical video data into actionable insights, aimed at enhancing surgical outcomes across hospitals and healthcare systems.Theator Inc. was founded in 2018 in Palo Alto, US, and focuses on providing innovative solutions for surgical teams. The company has raised a total of USD 24.00 mn in funding, most recently securing USD 24.00 mn in Series A funding on July 22, 2022, led by Insight Partners, with participation from investors including Blumberg Capital and Mayo Clinic. CEO Tamir Wolf co-founded the company, bringing a vision of transforming surgical education and operations through technology.Theator offers a comprehensive Surgical Intelligence platform that transforms surgical video data into actionable insights aimed at enhancing the quality of care in hospitals. Their core product automatically captures robotic and laparoscopic surgical videos, which are accessible through a customizable content management system and securely stored in a self-managed cloud. The platform serves multiple end-use cases, including continuous quality improvement by linking structured surgical videos to patient outcomes, operational efficiency through the standardization of surgical instruments, and enhanced graduate medical education via interactive feedback tools. Theator's solutions cater to a diverse clientele comprising hospitals and healthcare organizations across various global markets, including North America, Europe, and Asia, thereby addressing the pressing needs of surgical teams and educational institutions in the healthcare sector.The revenue model of Theator is primarily based on the deployment of its Surgical Intelligence platform through subscription-based agreements with healthcare institutions. Clients engage in transactions by subscribing to the platform, which allows access to a suite of features designed to improve surgical operations and training. These transactions include provisions for ongoing support and updates to the software, ensuring continual access to the latest functionalities. The firm's flagship offerings are designed to facilitate operational efficiencies and quality improvements, making them essential tools for healthcare providers striving to enhance surgical outcomes. Specific pricing structures are tailored to the needs of each institution, reflecting the comprehensive nature of the services provided by Theator in the surgical domain.In July 2022, Theator Inc. raised USD 24.00 mn in Series A funding to support its commercial expansion and boost the rollout of its Surgical Intelligence Platform in operating rooms and healthcare systems across North America. The company is focusing on enhancing its product offerings and aims to expand into new markets in Europe and Asia by the end of 2023. Future product releases are planned to enhance user engagement and operational capabilities in surgical settings.

## Funding rounds

- Series A, Jul 22, 2022, $24M — Insight Partners, Mayo Clinic, Blumberg Capital, StageOne Ventures, NFX, iAngels, ICON
- Series A, Jan 12, 2021, $15M — Insight Partners, Blumberg Capital, StageOne Ventures, NFX, KdT Ventures, iAngels
- Seed, Aug 5, 2019 — NFX
- Seed, Apr 17, 2019, $3M — StageOne Ventures, KdT Ventures, iAngels

## Investors

- StageOne Ventures (https://capitalatlas.ai/funds/stageone-ventures) — Seed, Series A
- KdT Ventures (https://capitalatlas.ai/funds/kdt-ventures) — Seed, Series A
- iAngels (https://capitalatlas.ai/funds/iangels) — Seed, Series A
- NFX (https://capitalatlas.ai/funds/nfx) — Seed, Series A
- Insight Partners (https://capitalatlas.ai/funds/insight-partners) — Series A
- Blumberg Capital (https://capitalatlas.ai/funds/blumberg-capital) — Series A
- Mayo Clinic — Series A
- ICON — Series A